Addendum

Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94

Status
Status: Commission completed
Project no.
A20-33
Last updated

Report documents

  1. Addendum

    Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94

    published on
    Document type
    PDF document, 243 kB, EN, not accessible

Dossier assessment

Indication:

Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy

Result of dossier assessment:

Due to new information from the commenting procedure now hint of a non-quantifiable added benefit.

Additional information

Federal Joint Committee (G-BA)

2020-05-14 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-33
Commission
Commission awarded on 24.03.2020 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-94
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form